PRODUCTS
Tongxinluo Capsules
Shensong Yangxin Capsules
Qili Qiangxin Capsule
Lianhua Qingwen Capsules


  • Generic Name:Tongxinluo Capsules

  • Approval No.:GYZZ Z19980015

  • Strength: 0.26g/capsule

  • Administration and Dosage: For oral administration, 2-4 capsules once, 3  times daily.

  • Shelf life: 36 months

  • Ingredients: Ginseng, Leech, Scorpion, Red Peony Root, Cicada Slough,  Ground Beetle, Centipede, Sandalwood, Rosewood, Frankincense  Olibanum(processed), Spine Date Seed (stir-baked), Borneol

  • Functions and Indications:To replenish qi and promote blood circulation,  and dredge meridians to kill pain. It is used for angina pectoris in coronary  heart disease caused by a deficiency of heart-qi and blockage of meridians by  stagnated blood with manifestations of constriction, fixed stabbing or colic  pain in the chest, palpitation, spontaneous sweating, shortness of breath,   lassitude, dark purple tongue or ecchymosis, thready and unsmooth pulse or  knotted and intermittent pulse; stroke due to a deficiency of qi and stagnated  blood blocking meridians with manifestations of hemiplegia or numbness of one  side of the body, deviated mouth and tongue and dysphasia.


The key innovative theoretic recipe study on "Study on Treatment of Coronary Heart Disease with Tongxinluo Capsules" has won a Second-class Prize of the National Science and Technology Progress Award in 2000.


The modern ultra-fine micronization technology "Ultra-fine Micronization Technology for Insect Drugs and its Applications" won a Second-class Prize of the National Technology Invention in 2007.

  • Listed in the List of National Essential Drugs

  • A Class A Product in the National Health Insurance Program

  • A National Level Key New Product

  • A TCM Patent Drug Must be Available in Emergency Department of All TCM Hospitals around the Country

  • A Confidential and High-tech Product of the Ministry of Science and Technology

Guideline/Standard Therapy/Clinical Route

  • TCM Clinical Diagnosis and Treatment Guide on Acute Myocardial Infarction (2016)
  • Guide on Reasonable Medication for Coronary Heart Disease (Edition 2)

Textbooks

Integrated Chinese and Western Internal Medicine (Edition III, New Century)

Expert Consensus Documents

  • Expert Consensus Document on Diagnosis and Treatment of Atherosclerosis through Integrated Chinese and Western Medicine
  • Chinese Expert Consensus Document on Diagnosis and Treatment of Coronary Microvascular Diseases (2017)
  • Expert Consensus Document on Diagnosis and Treatment of Acute Myocardium Infarction through Integrated Chinese and Western Medicine
  • Chinese Expert Consensus Document on Diagnosis and Treatment of Coronary Spasm Syndrome
  • Chinese Expert Consensus Document on Diagnosis and Treatment of Perioperative Myocardial Injuries after Percutaneous Coronary Intervention
  • Expert Consensus Document on Diagnosis and Treatment of Chronic Cerebral Ischemia through Integrated Chinese and Western Medicine
  • Chinese Expert Consensus Document on Standardized Diagnosis and Treatment of Acute Coronary Syndrome in the Elderly (≥75)

Protection of Blood

It has such functions as anti-coagulation and anti-thrombosis, reducing the resistance to Aspirin, reducing liquid and anti-inflammation. It has synergetic effects when it is used together with statin products.

Protection of Myocardia

It has such functions as dilating the coronary artery, protecting the myocardial micro vessels, improving myocardial ischemia, alleviating angina even with satisfactory effects on repeated attacks of angina that are difficult to treat, improving the myocardial recovery after myocardial infarction, and reducing the incidences of malignant arrhythmia, heart failure and sudden death.

Protection of Blood Vessels

It has such functions as protecting the endothelial cells of the blood vessels, inhibiting stable plaques, relieving spasms and preventing myocardial infarction and cerebral infarction.

Protection of Brains

It has such functions as increasing the blood supply to the brains, protecting capillaries, improving the cerebral ischemia caused by cerebral arteriosclerosis, treating cerebral infarction, promoting the recovery of neurological functions, preventing recurrence of stroke, protecting the cerebral tissues, and effectively treating vascular dementia and senile dementia.

Soft plaques diagnosed by ultrasonography or CT can easily rupture and resulting in vulnerable plaque that can cause acute myocardial infarction and cerebral infarction. About 70% of the ruptures of the artery plaques occur in patients with a stenosis degree of less than 50%. It is a worldwide problem in the international medical field to effectively inhibit stable vulnerable plaques. The study of Academician Zhang Yun has proved that the high, medium and low dosages of Tongxinluo Capsules have equivalent therapeutic effects in stabilizing vulnerable plaques compared with that of statins. The paper for this study has been published in American Journal of Physiology and has drawn attention from all around the international medical field. The editorial department of American Journal of Physiology calls this "the challenge of the modern medicine by traditional Chinese medicine". This study brings hope to the high-risk patients who may develop coronary heart disease in the future.

An important breakthrough has been made by the prospective, random, double blind, placebo control and multi-center clinical study in 1,200 cases for the intervention of carotid arterial plaques by Tongxinluo.

The participating organizations include 30 Tier Three Class A hospitals all around the country led by the Qilu Hospital of Shandong University and the Fuwai Hospital of Chinese Academy of Medical Sciences.

The study was hosted by Academician Zhang Yun, the President of the College of Medicine of Shangdong University.

The conclusions are that the use of Tongxinluo in sub-clinical patients suffering from arteriosclerosis can safely and effectively reduce the carotid artery intima-media thickness, the plaque area and the vascular remodeling index, and significantly reduce the major cardiovascular events, especially the incidence of unstable angina pectoris.

Effective myocardial perfusion may not necessarily be achieved after the large vessels of the coronary artery have been opened after the intervention therapy for acute myocardial infarction (the placement of the heart stent). The no-reflow at the myocardium cause by any damages at the myocardial micro-vessels is one of the most important reasons of such severe complications such as arrhythmia, heart failure and sudden death. This is also a common difficult problem and focus of the international medical field. The characteristic advantage of Tongxinluo Capsules in protecting the capillaries is that this product has proven effects in the treatment of acute myocardial infarction and promoting the recovery of the ischemic myocardium and improving the heart functions. This shows the important role of this product in solving this international problem.

The head of this clinical study is Professor Yang Yuejin of Fuwai Hospital of Chinese Academy of Medical Sciences.

The leading hospital is the Fuwai Hospital of Chinese Academy of Medical Sciences.

  • The study results show that the 24h ECG shows the complete drop rate of the elevated ST section is 65.74% vs 45.95%.
  • The nuclide scanning shows increased myocardial perfusion.
  • The myocardial contrast echocardiography shows increased myocardial microcirculation perfusion.
  • The ultrasound wall motion analysis shows improved cardiac wall motion and contraction functions.

  Read this leaflet carefully, and take this medicine under the doctor or  pharmacists’ direction

  [Drug Name]

  Generic Name: Tongxinluo Capsules

  Chinese Pinyin: Tongxinluo Jiaonang

  [Ingredients] Ginseng, Leech, Scorpion, Red Peony Root, Cicada Slough,  Ground Beetle, Centipede, Sandalwood, Rosewood, Frankincense  Olibanum(processed), Spine Date Seed (stir-baked), Borneol

  [Description] Capsules with brown powdered content; odour, aromatic,  slightly stinking; taste, slightly salty and bitter.

  [Functions and Indications ] To replenish qi and promote blood circulation,  and dredge meridians to kill pain. It is used for angina pectoris in coronary  heart disease caused by a deficiency of heart-qi and blockage of meridians by  stagnated blood with manifestations of constriction, fixed stabbing or colic  pain in the chest, palpitation, spontaneous sweating, shortness of breath,   lassitude, dark purple tongue or ecchymosis, thready and unsmooth pulse or  knotted and intermittent pulse; stroke due to a deficiency of qi and stagnated  blood blocking meridians with manifestations of hemiplegia or numbness of one  side of the body, deviated mouth and tongue and dysphasia.

  [Strength] 0.26g/capsule

  [Administration and Dosage] For oral administration, 2-4 capsules once, 3  times daily.

  [Adverse Reactions] Stomach discomfort may emerge in individual  patient.

  [Contraindication] Contraindicated for patients with hemorrhage, pregnant  women, women during periods, and stroke patients from yin deficiency and fire  hyperactivity.

  [Precautions] Take the medicine after meals if the stomach is  discomfortable after taking it.

  [Pharmacological Actions] Non-clinical pharmacodynamics test showed that:  It can decrease the degree of myocardial ischemia (MI) of canine and dog model  of acute myocardial infarction, diminish the extent of myocardial ischemia (MI)  and improve oxygen-supply and blood-supply, increase coronary blood flow(CBF)  and the function of left ventricle; It can diminish the area of no-reflow after  acute myocardial infarction and reperfusion in the experiment with mini-swine  model and decrease the size of myocardial infarction(MI); It can restrain  proliferation of myocardial collagenous fibers after myocardial infarction in  rats, diminish deposition of collagen protein, decrease the content of  AngiotensinⅡon cardiac muscle (CM), restrain reconstruction of cardiac ventricle  and improve the function of heart; For local cerebral ischemic rat model, it can   diminish the extent of infarction, decrease permeability of cerebral vessels and  brain edema; For global cerebral ischemic in mice, it can mitigate pathological  lesions such as denaturalization and necrosis of nerve cell and less of nissl  body, improve neuroethology, protect ischemic brain tissue, increase the  activity of Superoxide dismutase (SOD) of brain tissue, and reduce the content  of malondialdehyde (MDA); For rat with hyperlipemiat, it can decrease total  cholesterol and low density lipoprotein (LDL), increase high density  lipoprotein(HDL), restrain thrombosis and platelet aggregation in rat’s  body.

  In addition, it is shown by the exploratory study of mechanism of action  for the medicine that: for rat model with cerebral middle artery thrombus, it  can reduce the content of excitatory amino acid and endothelin(ET), restrain the  expression of endothelin gene, for the cerebral ischemic model of rat with  middle cerebral artery thrombus, it can promote the expression of vascular  endothelial growth factor (VEGF), protect the capillary endothelial cell in  brain and promote neogenesis of blood capillary; Improve the endothelium  function of atherosclerosis in rabbit model, and decrease the damage to the   function of endothelium dependent vasodilatation of hypercholesterolemia.  Through improving the expression of endothelial nitricoxide synthase (eNOS) gene  in myocardial ischemic mice, it can increase the activity of endothelial  nitricoxide synthase (eNOS) and the level of nitric oxide (NO) in blood plasma  and tissue; It can decrease the level of total cholesterol (TC) in blood, LDL  cholesterol (LDL-C) as well as endothelin (ET) and increase the level of NO  through restraining the expression of mitogen-activated protein kinase (MAPK)   and vascular intima proliferation after angioplasty in rabbit; For vulnerable  plaques rabbit model, the medicine can play roles in stabilizing the vulnerable  plaque though decreasing intracellular lipid content in plaque as well as  blood-fat and plasma fibrinogen level, increasing the thickness of plaque  fiberous coat and restraining the expression of inflammatory factor; It can  restrain coronary artery spasm (CAS) of mini-swine induced by thrombotonin  (5-HT); Through the above mentioned various functions, the medicine can exert  its effect on protecting heart and brain as well as restraining the formation of   thrombus.

  [Storage] Preserve in tightly closed containers.

  [Package] Aluminium-plastic package, 30 capsules/box.

  [Shelf life] 36 months

  [Executive Standard] Chinese Pharmacopoeia 2010, VolumeⅠ

  [Approval No.] GYZZ Z19980015

  [Manufacturer]

  Company name: Shijiazhuang Yiling Pharmaceutical Co., Ltd.

  Manufacture address: No.238 Tianshan street, New and high development area,  Shijiazhuang, Hebei, China.

  Postcode: 050035

  Tel: 800 8038581 +86 311 85901719 400 8165108

  Fax:+86 311 85901719

  Registration address: No.238 Tianshan street, New and high development  area, Shijiazhuang, Hebei, China.

  URL: http://www.yiling.cn

 

  Shijiazhuang Yiling Pharmaceutical Co., Ltd.